Enzymatica AB: New results from Enzymatica's in vitro study: ColdZyme also deactivates corona virus
April 11 2018 - 2:45AM
Press Release
April 11, 2018
New results from Enzymatica's in
vitro study: ColdZyme also deactivates corona virus
Today Enzymatica announced the
results of an in vitro study demonstrating the ability of ColdZyme®
Mouth Spray to deactivate human corona virus - one of the most
common cold virus families. Along with the in
vitro results from a study published in the autumn of
20171, ColdZyme has been shown to be able to deactivate over 90
% of the known viruses that cause colds.
The current results, which are being presented
today at Ear-Nose-and-Throat days in Linköping2, show
that ColdZyme deactivates human corona virus and reduces the
cytopathic (cell damaging) effect by 99.9 % in
vitro. The corona virus is potentially dangerous because in
addition to the common cold, it also causes diseases such as SARS
(Severe acute respiratory syndrome), and MERS
(Middle East respiratory syndrome), which
is a contagious pneumonia.
"Even
if the current in vitro results cannot be
directly translated into clinical efficacy, it is very interesting
that ColdZyme is able to effectively deactivate the absolute
majority of our most common cold viruses. These results help us to
better understand ColdZyme's preventive effect and its ability to
reduce the duration of colds," says Fredrik Lindberg, CEO of
Enzymatica.
The results regarding the corona virus complement
previously published in vitro data, which
showed that ColdZyme also deactivates four other common virus
families that cause colds. Thus ColdZyme has been shown to be 91.7
% effective in deactivating rhinovirus type 1A , 92.8 % effective
for rhinovirus type 42, 96.9 % for human influenza A virus H3N2,
99.9 % for RSV virus, 64.5 % effective for adenovirus type 2 and
99.9 % effective for human corona virus, without any cell-damaging
effect. In summary, ColdZyme has been shown to be effective against
more than 90 % of our most common cold viruses. All in vitro experiments were carried out by an
independent, accredited and certified laboratory.
The in vitro study was based
on standardized and validated methods developed to resemble the
in vivo environment in the mouth and
throat, where viruses attach, invade the cells and cause colds.
ColdZyme, which consists of glycerol and trypsin, an enzyme found
in Arctic cod, forms a barrier in the throat against the cold
virus. ColdZyme's effect is believed to be due in part to the
ability of trypsin to cleave proteins on the surface of the virus
particles that are important for their ability to infect cells.
This can prevent colds because the virus particles are unable to
bind to receptors on the surface of the cells.
1)
Stefansson B,
Gudmundsdottir A, Clarsund M (2017) A medical device forming a
protective barrier that deactivates four major common cold
viruses. Virol Res Rev 1: DOI:
10.15761/VRR.1000130
2)
Stefansson et al, ColdZyme forms a protective barrier in the throat
that deactivates five major common cold viruses, Congress of the
Swedish Association of Otolaryngology, 2018, see attached abstract
och poster pdf.
The information in this press release is information that
Enzymatica is obliged to make public pursuant to the EU Market
Abuse Regulation. The information was submitted for publication,
through the agency of the contact person set out above, at 8:45
a.m. on April 11, 2018.
For
more information, please contact:
Fredrik Lindberg, CEO, Enzymatica AB
Tel: +46 (0)708-86 53 70 | Email:
fredrik.lindberg@enzymatica.com
About Enzymatica AB
Enzymatica AB is a Swedish life science company that develops and
sells medical devices for infection-related diseases. The products
are based on a barrier technology that includes marine enzymes. The
company's first product is ColdZyme® Mouth Spray, which can prevent
colds and reduce the duration of disease. The product has been
launched in about ten markets. The strategy is to continue to grow
by strengthening the Company's position in existing markets and
expanding into new geographic markets through established partners.
The company has its headquarters in Lund and is listed on Nasdaq
First North. For more information,
visit: www.enzymatica.com.
Enzymatica's certified advisor is Erik Penser
Bank.
Press release Study inactivation of
corona virus Eng 180411
ColdZyme Corona virus Poster 180411
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Enzymatica AB via Globenewswire
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Oct 2024 to Nov 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Nov 2023 to Nov 2024
